Skip to content

Psilocybin for depression: all studies

Page 30 of 49: studies 291 to 300 of 490, newest first. Back to the psilocybin for depression overview

Research

HOPE: A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer.

Journal of Pain and Symptom Management September 1, 2023 Benjamin R. Lewis, Eric L Garland, Kevin Byrne et al. 60 citations

Psilocybin-assisted psychotherapy shows promise in treating depression and existential distress in people with serious medical illness. However, its individual-based methodology poses challenges for scaling and resource availability. The HOPE trial (A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer) is an Institutional Review Boards-approved open-label feasibility...

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology September 1, 2023 Guy M. Goodwin, Megan Croal, David Feifel et al. 166 citations

Psilocybin is being investigated as a treatment in adults with treatment-resistant depression (TRD). Withdrawal from serotonergic antidepressant drugs is a common prerequisite for taking part in trials of psilocybin due to the possibility of ongoing antidepressant drugs altering the psychedelic effect. This phase II, exploratory, international, fixed-dose, open-label study explored the safety,...

Natural psychedelics in the treatment of depression; a review focusing on neurotransmitters.

Fitoterapia September 1, 2023 Samane Jahanabadi, Shayan Amiri, Mehdi Karkeh-Abadi et al. 14 citations

Natural psychedelic compounds are emerging as potential novel therapeutics in psychiatry. This review will discuss how natural psychedelics exert their neurobiological therapeutic effects, and how different neurotransmission systems mediate the effects of these compounds. Further, current therapeutic strategies for depression, and novel mechanism of action of natural psychedelics in the...

Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.

Psychedelic medicine (New Rochelle, N.Y.) September 1, 2023 Zachary Herrmann, Adam W. Levin, Steven P Cole et al. 9 citations

Mental health problems including depression, anxiety, suicide, and burnout are common among health care providers. Resilience and well-being are factors thought to protect against these incidents. Clinical trials and naturalistic studies of psychedelic compounds have shown decreases in depression, anxiety, and suicidality while suggesting improvements in well-being. This secondary analysis of a...

Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin.

Cureus September 1, 2023 Nm Mahmudul Alam Bhuiya, Robin J Jacobs, Karina Wang et al. 3 citations

Background Psilocybin has been studied for its potential therapeutic benefits, particularly for the treatment of psychiatric disorders such as anxiety, depression, and obsessive-compulsive disorder. While more research is needed as psilocybin-assisted therapy becomes more prevalent, future pharmacists will probably be involved at some level. At present, pharmacists receive minimal training on...

Single-Dose Psilocybin Treatment for Major Depressive Disorder

JAMA August 31, 2023 Charles L. Raison, Gerard Sanacora, Joshua Woolley et al. 493 citations

Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were...

DOI: 10.1001/jama.2023.14530 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Clinical depression treatment Psychedelic medicine Mental health research +1

Psilocybin therapy for treatment resistant depression: prediction of clinical outcome by natural language processing

Psychopharmacology August 22, 2023 Robert F. Dougherty, Patrick Clarke, Merve Atli et al. 21 citations

Abstract Rationale Therapeutic administration of psychedelics has shown significant potential in historical accounts and recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilocybin, in participants with...

A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder

Journal of Psychoactive Drugs August 18, 2023 Raul Escamilla, María Eva González-Trujano, Jesús M. González Mariscal et al. 7 citations

The pharmacological treatment of depression consists of taking antidepressant drugs for prolonged periods; its modest therapeutic effect can often be associated with significant adverse effects, while its discontinuation can lead to relapses. Psilocybin is today a novel and breakthrough therapy for major depression. It is a natural alkaloid in Psilocybe mushrooms, which are endemic to Mexico....

DOI: 10.1080/02791072.2023.2246459 (opens in new tab) Psychedelic therapy Major depression Psilocybe mushrooms Psychedelic medicine +3

Psilocybin‐assisted psychotherapy for treatment‐resistant depression: Which psychotherapy?

International Journal of Mental Health Nursing August 17, 2023 Marie Crowe, Jenni Manuel, Dave Carlyle et al. 6 citations

Abstract This perspective paper explores the choice of psychotherapy for psilocybin‐assisted psychotherapy for treatment‐resistant depression. There is evidence to support the use of some psychotherapies in treating ‘treatment‐resistant’ depression, and emerging evidence for the efficacy of psilocybin. The next step which is the focus of this paper is to identify psychotherapies that are both...

The use of psilocybin in the treatment of psychiatric disorders – review

Journal of Education, Health and Sport August 15, 2023 Justyna Woźniak, Rafał Bogacz, Magdalena Gaik et al.

Introduction: The word “psychedelic” derives from the Greek language and can be loosely translated as “mind manifesting” which is to convey that these substances allow the mind to unleash its hidden potential. Psilocybin is considered to be a “classic psychedelic” and is most commonly found in the form of so-called “magic mushrooms”. Due to its unique properties psilocybin has been used during...